Amphastar Pharmaceuticals Inc AMPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
-
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
-
Amphastar Receives Warning Letter from FDA for Facility's Manufacturing Practices
-
Amphastar Pharmaceuticals Gets FDA Approval for Over-The-Counter Nasal Spray for Opioid Overdose
Trading Information
- Previous Close Price
- $25.35
- Day Range
- $25.06–25.55
- 52-Week Range
- $16.65–29.52
- Bid/Ask
- $24.20 / $27.48
- Shares Outstanding
- 42.54M
- Market Cap
- $1.08B
- Volume/Avg
- 374,218 / 463,378
Key Statistics
- Price/Earnings (Normalized)
- 8.49
- Price/Sales
- 1.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 9.28%
Company Profile
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,976
- Website
- https://www.amphastar.com
Valuation
|
Metric
|
AMPH
|
|---|---|
Price/Earnings (Normalized) | 8.49 |
Price/Book Value | 1.40 |
Price/Sales | 1.61 |
Price/Cash Flow | 5.80 |
Price/Earnings
AMPH
Financial Strength
|
Metric
|
AMPH
|
|---|---|
Quick Ratio | 1.66 |
Current Ratio | 2.40 |
Interest Coverage | 4.55 |
Quick Ratio
AMPH
Profitability
|
Metric
|
AMPH
|
|---|---|
Return on Assets (Normalized) | 8.38% |
Return on Equity (Normalized) | 18.00% |
Return on Invested Capital (Normalized) | 10.54% |
Return on Assets
AMPH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|PBh>M%<d | LOCK|<Ty@ | $66B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|c!?hbjT? | LOCK|pBBy | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|>t#bzbx | LOCK|TMv | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|S<J^sXCb | LOCK|!vc | $29B | |||
| Viatris Inc
VTRS
| LOCK|tCs@%S | LOCK|VCg | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|&Dr | LOCK|B! | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|>!<$g< | LOCK|Y>^ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|vQc^!j$ | LOCK|Dp | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|!>BQ%g | LOCK|LS@k# | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|NCpZ@> | LOCK|%$> | $2B |
United States